1. A method of providing error correction in an integrated circuit (IC) to enable the replacement of a defective logic function implemented within the IC, the method comprising:
providing an embedded field programmable gate array (FPGA) in the IC to perform logic error correction;
providing registers and associated circuitry designed to manipulate a scanned data stream;
identifying a defective logic function within the IC;
programming the embedded FPGA to replace the defective logic function;
identifying all inputs in an input cone of logic of the defective logic function;
directing all inputs in the input cone of logic of the defective logic function into the embedded FPGA, such that the embedded FPGA replaces the defective logic function with an error corrected version of the defective logic function, wherein said directing of all inputs in the input cone of logic of the defective logic function into the embedded FPGA includes:
placing a logic macro implemented in the IC into a wait state; and
scanning data from the defective logic function into the FPGA and the registers and associated circuitry to implement error correction of the defective logic function; and,
identifying all outputs in an output cone of logic of the defective logic function; directing an output of the FPGA to the output cone of logic of the defective logic function, such that logic error correction is provided within the embedded FPGA structure of the IC,
wherein a scan chain defines a data path through the IC, and a feedback loop is formed to direct corrected data of the scan chain to a register boundary of the defective logic function, whereupon the logic macro discontinues the wait state and resumes normal processing.
2. The method of claim 1, wherein a scan chain defines a data path through the IC, and corrected data of the scan chain is scanned back around, upstream or downstream, to an origin of the corrected data.
3. The method of claim 1, wherein a plurality of said embedded FPGAs are operatively connected for receiving scan chain data from one or more logic functions within an IC.
4. The method of claim 1, wherein a plurality of scan chains define a plurality of data paths through the IC, and a plurality of said embedded FPGAs being operatively connected for receiving said connected scan chain data from one more loge functions within said IC to correct data in the plurality of scan chains.
5. The method of claim 1, wherein a plurality of scan chains define a plurality of data paths through the IC, and data to be corrected in the plurality of scan chains are multiplexed into a single dedicated FPGA that is time multiplexed between the plurality of scan chains.
6. The method of claim 1, wherein a plurality of scan chains define a plurality of data paths through the IC, and data to be corrected in the plurality of scan chains are multiplexed into a single FPGA that is time multiplexed between the plurality of scan chains and also with normal system functions performed by the single FPGA.
7. The method of claim 1, further including:
identifying defective logic functions of the IC;
tracing a cone of logic of each identified defective logic function forward and backward to register boundaries; and,
selecting and implementing a correction solution comprising one or more of: correcting bad data bits, correcting upstream data, or correcting downstream data.
8. The method of claim 1, further including:
identifying defective logic functions in a logic macro implemented in the IC;
analyzing dataflow through the IC with respect to each identified defective logic function; and
identifying an optimum stage in the IC logic macro for which a logic breakpoint may be inserted to enable replacement of a defective logic function of said identified defective logic functions.
9. The method of claim 8, wherein the logic breakpoint is set by a comparison of a program count of a program counter for the IC with a preselected count of the program counter.
10. The method of claim 8, wherein the logic breakpoint is set based upon a preselected number of clock cycles of a clock of the IC.
11. The method of claim 1, further including:
identifying defective logic functions in a logic macro implemented in the IC;
analyzing dataflow though the IC with respect to each identified defective logic function; and
identifying an optimum point in a timing path of a defective logic function to insert a logic breakpoint to enable replacement of the defective logic function.
12. The method of claim 11, wherein the logic breakpoint is set by a comparison of a program count of a program counter for the IC with a preselected count of the program counter.
13. The method of claim 11, wherein the logic breakpoint is set based upon a preselected number of clock cycles of a clock of the IC.
14. The method of claim 1, further including extracting register transfer language (RTL), identifying and implementing RTL updates that are required and feasible.
15. The method of claim 1, wherein a plurality of scan chains define a plurality of data paths through the IC, and including using separate scan chain clocks and a separate FPGA clock to advance the data of one scan chain at a time independently of other scan chains and the FPGA.
16. The method of claim 1, wherein the FPGA includes an input correction register and an output correction register, and further including storing a program in a RAM to program which bits of a scan chain data stream are used to set the input correction register of the FPGA, and which bits of the scan chain data stream are replaced with bits from the output correction register of the FPGA.
17. The method of claim 16, wherein a bit mapping generated from the scan chain data steam corresponding to a stream of data output from the defective logic function passes through the input correction register, said scan chain data stream being captured in input latches of the input correction register if a program count of a program counter of the IC matches a preselected count.
18. The method of claim 1, further including providing a multiplexer at an output of the FPGA, and if a program count of a program counter of the IC matches a preselected count, using the multiplexer to replace bit(s) of a scan chain bit stream with bit(s) at the output of the FPGA.
19. A method of debugging and repairing logic errors of an integrated circuit (IC) performing a logic function, and having a system clock, the method comprising the steps of:
incorporating a scan chain function circuit in the IC;
setting a plurality of logic breakpoints in the logic function;
detecting a logic error in die IC;
cycling a scan chain data path through the IC and capturing an input data stream of the scan chain data path in a set of latches feeding an embedded field programmable gate array (FPGA);
initiating a waiting state of the IC logic function while a logic function error correction is identified and implemented by the embedded FPGA within a single clock cycle of a system clock for the IC;
repeating the cycling of the scan chain data path by feeding said input data stream of the scan chain data path to the embedded FPGA with a repaired logic function; and
resuming normal execution and clocking of the IC logic function,
wherein a plurality of scan chain data paths are provided through the IC, and with one or more said embedded FPGAs being operatively connected for receiving respective scan chain data from one more logic functions throughout the IC to correct data in the plurality of scan chain data paths.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An isolated g protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1, or a salt thereof:
2. A partial peptide of the G protein-conjugating receptor protein according to claim 1, or a salt thereof.
3. An isolated polynucleotide comprising a polynucleotide encoding the G protein-conjugating receptor protein according to claim 1.
4. The polynucleotide according to claim 3 which is a DNA.
5. The polynucleotide according to claim 3 having the nucleotide sequence represented by SEQ ID NO.2.
6. A recombinant vector comprising the polynucleotide according to claim 3.
7. A transformant transformed with the recombinant vector according to claim 6.
8. A method for producing the G protein-conjugating receptor protein according to claim 1 or a salt thereof, comprising cultivating the transformant having an expressible recombinant vector comprising a nucleic acid which encodes for said protein, under suitable conditions for producing said protein, and for sufficient time to generate the G protein-conjugating receptor protein according to claim 1.
9. An antibody against the G protein-conjugating receptor protein according to claim 1 or the partial peptide or a salt thereof.
10. The antibody according to claim 9 which is a neutralizing antibody which inactivates the signal transmission of the G protein-conjugating receptor.
11. A diagnostic composition comprising the antibody according to claim 9.
12. A ligand for the G protein-conjugating receptor protein according to claim 1 or a salt thereof which is obtainable by using the G protein-conjugating receptor protein according to claim 1 or the partial peptide or a salt thereof in a screening assay.
13. A pharmaceutical composition comprising a ligand for the G protein-conjugating receptor protein according to claim 12 and a pharmaceutically acceptable carrier, diluent or excipient.
14. A method for determining a ligand for the G protein-conjugating receptor protein according to claim 1 or a salt thereof, comprising using the G protein-conjugating receptor protein according to claim 1 or the partial peptide or a salt thereof in a screening assay.
15. A method for screening a compound or a salt thereof which is capable of altering the binding affinity between a ligand and the G protein-conjugating receptor protein according to claim 1 or a salt thereof, comprising contacting said compound with said ligand or said protein or the partial or a salt thereof, and detecting any alteration in binding between said ligand and said protein.
16. A screening kit for a compound or a salt thereof capable of altering the binding affinity between a ligand and the G protein-conjugating receptor protein according to claim 1 or a salt thereof, comprising the G protein-conjugating receptor protein according to claim 1 or the partial peptide or a salt thereof.
17. A compound or a salt thereof capable of altering the binding affinity between a ligand and the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 or a salt thereof, which is obtainable by using the screening method according to claim 15.
18. A pharmaceutical composition comprising a compound or a salt thereof of claim 17 and a pharmaceutically acceptable carrier, diluent or excipient.
19. An isolated polynucleotide hybridizing with the polynucleotide according to claim 3 under a high stringent condition.
20. An isolated polynucleotide comprising a nucleotide sequence or a part thereof which is complementary with the polynucleotide according to claim 3.
21. A method for quantifying an mRNA of the G protein-conjugating receptor protein according to claim 1, comprising using the polynucloeotide or a part thereof encoding for said protein as a probe.
22. A method for quantifying the G protein-conjugating receptor protein according to claim 1, comprising using an antibody which binds to said protein in an assay.
23. A method for diagnosing a disease related to a function of the G protein-conjugating receptor protein according to claim 1, comprising using a quantification method and detecting said protein or mRNA encoding for said protein.
24. A screening method for a compound or a salt thereof capable of altering the expression level of the G protein-conjugating receptor protein according to claim 1, comprising combining said compound with a transformed host cell which can express said protein, and detecting mRNA encoding for said protein.
25. A screening method for a compound or a salt thereof capable of altering the amount of the G protein-conjugating receptor protein according to claim 1 in a cell membrane, comprising combining said compound with a transformed host cell which can express said protein, and detecting said protein.
26. A compound or a salt thereof capable of altering the expression level of the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1, which is obtainable by using the screening method according to claim 24.
27. A compound or a salt thereof capable of altering the amount of the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 in a cell membrane, which is obtainable by using the screening method according to claim 25.
28. A pharmaceutical composition comprising a compound or a salt thereof capable of altering the expression level of the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1, which is obtainable by using the screening method according to claim 24.
29. A pharmaceutical composition comprising a compound or a salt thereof capable of altering the amount of the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 in a cell membrane, which is obtainable by using the screening method according to claim 25.
30. A pharmaceutical composition for preventing or treating a disease in central nervous system, inflammatory disease, circulatory disease, cancer, diabetes or infertility comprising an effective amount of an inhibitor of a G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1, and a pharmaceutically acceptable carrier, diluent or excipient.
31. A method for preventing or treating a disease in the central nervous system, inflammatory disease, circulatory disease, cancer, diabetes or infertility, comprising administering to a mammal in need thereof an effective amount of a compound or a salt thereof capable of altering the binding affinity between a ligand and the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 or a salt thereof, which is obtainable by using the screening method according to claim 15.
32. A method for preventing or treating a disease in the central nervous system, inflammatory disease, circulatory disease, cancer, diabetes or infertility, comprising administering to a mammal in need thereof an effective amount of a compound or a salt thereof capable of altering the expression level of the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1, which is obtainable by using the screening method according to claim 24.
33. A method for preventing or treating a disease in the central nervous system, inflammatory disease, circulatory disease, cancer, diabetes or infertility, comprising administering to a mammal in need thereof an effective amount of a compound or a salt thereof capable of altering the amount of the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 in a cell membrane, which is obtainable by using the screening method according to claim 25.
34. A method for making a pharmaceutical for preventing or treating a disease in central nervous system, inflammatory disease, circulatory disease, cancer, diabetes or infertility comprising combining a compound or a salt thereof capable of altering the binding affinity between a ligand and the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 or a salt thereof, which is obtainable by using the screening method according to the claim 15, with a pharmaceutically acceptable carrier, diluent or excipient.
35. A method for making a pharmaceutical for preventing or treating a disease in central nervous system, inflammatory disease, circulatory disease, cancer, diabetes or infertility comprising combining a compound or a salt thereof capable of altering the binding affinity between a ligand and the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 or a salt thereof, which is obtainable by using the screening method according to the claim 24, with a pharmaceutically acceptable carrier, diluent or excipient.
36. A method for making a pharmaceutical for preventing or treating a disease in central nervous system, inflammatory disease, circulatory disease, cancer, diabetes or infertility comprising combining a compound or a salt thereof capable of altering the binding affinity between a ligand and the G protein-conjugating receptor protein comprising an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO.1 or a salt thereof, which is obtainable by using the screening method according to the claim 25, with a pharmaceutically acceptable carrier, diluent or excipient.